A recent World Health Organization (WHO) study, published in eBioMedicine, has identified 17 priority pathogens that are endemic in various communities and urgently require new vaccines. This marks WHO’s first global effort to systematically prioritize endemic pathogens for vaccine development,…
Kashiv BioSciences, LLC, a globally integrated biopharmaceutical company, has appointed Dr. Sandeep Nilkanth Athalye as its new Global Chief Executive Officer. With over 20 years of experience in strategic and operational roles within the pharmaceutical industry, Dr. Athalye will lead…
Medidata, a brand of Dassault Systèmes and a leading provider of clinical trial solutions, has partnered with Cogstate, a leader in neuroscience solutions, to transform clinical trials and outcome measurements for central nervous system (CNS) diseases, including neurodegenerative, psychiatric, motor,…
In its sixth year of collaboration with Girls Inc., Allergan Aesthetics, a subsidiary of AbbVie, is pleased to welcome SkinSpirit, a leading provider of medical aesthetics and skincare, to its initiative aimed at empowering girls to be strong, smart, and…
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central nervous system (CNS) diseases. Aliada’s lead investigational asset, ALIA-1758, is…
Walgreens is expanding its virtual healthcare service to enhance access for patients nationwide. As of October 1, Walgreens Virtual Healthcare is now available in 30 states, a significant increase from its initial launch in nine states. This expansion is designed…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940 (mRNA-4157), an individualized neoantigen therapy (INT), combined with KEYTRUDA® (pembrolizumab),…
Biogen Inc. (Nasdaq: BIIB) shared full results from its Phase 2 IGNAZ study on felzartamab, an investigational anti-CD38 monoclonal antibody, for IgA nephropathy (IgAN) treatment. Data revealed significant reductions in proteinuria, kidney function stabilization, and sustained treatment effects over 18…
LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, increasing its total number of CLIA-certified labs in the U.S. to four. This acquisition enhances LabGenomics’ strategic growth and expands its diagnostic services nationwide, particularly in molecular technology. In…
BioHub Maryland, an initiative aimed at accelerating the life sciences sector in the state, officially opened its new biopharmaceutical workforce training center on October 24 at 9808 Medical Center Drive in Rockville. The event featured Maryland Lt. Governor Aruna Miller…
Losing your sight can profoundly impact your life, affecting everything from connections to experiences. Our eyes serve as a window to the world, and when vision is lost, it can be a devastating experience for many individuals. Vision loss is…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company specializing in targeted therapies for RAS-driven cancers, has announced promising early data on RMC-9805, a selective inhibitor for the RAS(ON) G12D mutation. The preliminary safety and antitumor results for RMC-9805 were…